產(chǎn)品名稱 Abemaciclib mesylate - LKT Labs
產(chǎn)品貨號 A044178
產(chǎn)品價格 現(xiàn)貨詢價，電話：010-67529703
產(chǎn)品規(guī)格
產(chǎn)品品牌 lktlabs
產(chǎn)品概述
產(chǎn)品詳情 Abemaciclib mesylate

Description

Abemaciclib is a CDK4 and CDK6 inhibitor found to inhibit retinoblastoma phosphorylation, leading to G1/S arrest in ER+ breast cancer cells and to promote metabolic alterations in metastatic HR+ breast cancer cells.

Product Info

Cas No.

1231930-82-7
Purity

≥98%
Formula

C27H32F2N8 ? CH4O3S
Formula Wt.

602.71
Chemical Name

N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine methanesulfonate
Synonym

LY2835219 methanesulfonate
Solubility

DMSO:84 mg/mL; Water:100 mg/mL
Appearance

White powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Blue Ice

Downloads

MSDS

A044178 MSDS PDF
Info Sheet

A044178 Info Sheet PDF

References

Torres-Guzman R, Calsina B, Hermoso A, et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget. 2017 May 10. Epub ahead of print. PMID: 28537883

Tate SC, Burke TF, Hartman D, et al. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. Br J Cancer. 2016 Mar 15;114(6):669-679. PMID: 26978007

Knudsen ES, Hutcheson J, Vail P, et al. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jun 10. Epub ahead of print. PMID: 28620137
產(chǎn)品資料